

**LEGISLATIVE BUDGET BOARD**  
**Austin, Texas**

**FISCAL NOTE, 86TH LEGISLATIVE REGULAR SESSION**

**May 22, 2019**

**TO:** Honorable Dennis Bonnen, Speaker of the House, House of Representatives

**FROM:** John McGeady, Assistant Director    Sarah Keyton, Assistant Director  
Legislative Budget Board

**IN RE: HB2536** by Oliverson (Relating to transparency related to drug costs.), **As Passed 2nd House**

**No significant fiscal implication to the State is anticipated.**

The bill would require pharmaceutical drug manufacturers (PDMs) to annually report to the Health and Human Services Commission (HHSC) on the current wholesale acquisition costs of certain FDA-approved drugs sold in the state. HHSC would be required to develop a website to provide this information to the public. The bill would also require PDMs to report information on certain drug price increases. HHSC would be required to publish these reports online.

The bill would require Pharmacy Benefit Managers and Health Benefit Plan Issuers to submit reports to the Insurance Commissioner, who would be required to publish the combined aggregated data from those reports online.

The Employee Retirement System, Department of Insurance, The University of Texas System Administration, Texas A&M University System Administrative and General Office, and HHSC indicate that the provisions of the bill could be absorbed using existing resources.

**Local Government Impact**

No fiscal implication to units of local government is anticipated.

**Source Agencies:**        327 Employees Retirement System, 454 Department of Insurance, 529 Health and Human Services Commission, 710 Texas A&M University System Administrative and General Offices, 720 The University of Texas System Administration

**LBB Staff:** WP, CLo, JQ, BH, CMa